Yasushi Tanoue

507 total citations
15 papers, 295 citations indexed

About

Yasushi Tanoue is a scholar working on Molecular Biology, Hepatology and Hematology. According to data from OpenAlex, Yasushi Tanoue has authored 15 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Hepatology and 3 papers in Hematology. Recurrent topics in Yasushi Tanoue's work include Liver physiology and pathology (5 papers), Acute Myeloid Leukemia Research (3 papers) and Cancer Genomics and Diagnostics (3 papers). Yasushi Tanoue is often cited by papers focused on Liver physiology and pathology (5 papers), Acute Myeloid Leukemia Research (3 papers) and Cancer Genomics and Diagnostics (3 papers). Yasushi Tanoue collaborates with scholars based in Japan, United States and Sweden. Yasushi Tanoue's co-authors include Natsuko Ohtomo, Takako Nishikawa, Tomoaki Tomiya, Hitoshi Ikeda, Yukiko Inoue, Masao Omata, Naoko Watanabe, Yutaka Yatomi, Yukio Kume and Tatsuo Shimosawa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Yasushi Tanoue

14 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yasushi Tanoue Japan	8	173	68	62	60	55	15	295
Feng Hong China	11	158 0.9×	32 0.5×	64 1.0×	53 0.9×	34 0.6×	24	301
Myeong‐Jin Nam South Korea	7	233 1.3×	65 1.0×	33 0.5×	60 1.0×	41 0.7×	8	392
Cristina Bárcena Spain	8	145 0.8×	88 1.3×	158 2.5×	47 0.8×	43 0.8×	9	384
Brian Bridges United States	7	193 1.1×	49 0.7×	74 1.2×	33 0.6×	65 1.2×	8	389
Kisha Mitchell-Richards United States	8	126 0.7×	71 1.0×	50 0.8×	31 0.5×	62 1.1×	13	343
Chantal Rodgarkia‐Dara Austria	9	249 1.4×	61 0.9×	19 0.3×	38 0.6×	78 1.4×	9	371
Aislinn E. Treloar Canada	4	232 1.3×	78 1.1×	49 0.8×	55 0.9×	45 0.8×	4	431
Kyung Joo Cho South Korea	9	172 1.0×	109 1.6×	29 0.5×	30 0.5×	77 1.4×	15	317
Fudong Lv China	9	159 0.9×	84 1.2×	29 0.5×	39 0.7×	92 1.7×	13	312
Bijoya Sen India	8	165 1.0×	111 1.6×	48 0.8×	23 0.4×	58 1.1×	9	366

Countries citing papers authored by Yasushi Tanoue

Since Specialization

Citations

This map shows the geographic impact of Yasushi Tanoue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasushi Tanoue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasushi Tanoue more than expected).

Fields of papers citing papers by Yasushi Tanoue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasushi Tanoue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasushi Tanoue. The network helps show where Yasushi Tanoue may publish in the future.

Co-authorship network of co-authors of Yasushi Tanoue

This figure shows the co-authorship network connecting the top 25 collaborators of Yasushi Tanoue. A scholar is included among the top collaborators of Yasushi Tanoue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasushi Tanoue. Yasushi Tanoue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Yokoyama, Hisayuki, Noriko Fukuhara, Koji Ando, et al.. (2025). Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies. Blood Advances. 10(1). 262–272.

Yokoyama, Hisayuki, Noriko Fukuhara, Koji Ando, et al.. (2024). Abstract CT115: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort. Cancer Research. 84(7_Supplement). CT115–CT115. 1 indexed citations

Al‐Kali, Aref, Antoine N. Saliba, James M. Foran, et al.. (2023). Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. Blood. 142(Supplement 1). 3249–3249. 5 indexed citations

Shimizu, Toshio, Kan Yonemori, Takafumi Koyama, et al.. (2022). A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.. Journal of Clinical Oncology. 40(16_suppl). 3080–3080. 6 indexed citations

Yokoyama, Hisayuki, Koji Ando, Noriko Fukuhara, et al.. (2022). A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort. Blood. 140(Supplement 1). 6211–6212. 5 indexed citations

Arai, Jun, Kaku Goto, Yasushi Tanoue, et al.. (2018). Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells. International Journal of Cancer. 143(10). 2575–2583. 29 indexed citations

Arai, Jun, Kaku Goto, Yasushi Tanoue, et al.. (2017). Predominance of regorafenib over sorafenib: Restoration of membrane‐bound MICA in hepatocellular carcinoma cells. Journal of Gastroenterology and Hepatology. 33(5). 1075–1081. 29 indexed citations

Goto, Kaku, Dorcas A. Annan, Tomoko Morita, et al.. (2016). Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Scientific Reports. 6(1). 38407–38407. 16 indexed citations

Inoue, Yukiko, Tomoaki Tomiya, Takako Nishikawa, et al.. (2013). Induction of p53-Dependent p21 Limits Proliferative Activity of Rat Hepatocytes in the Presence of Hepatocyte Growth Factor. PLoS ONE. 8(11). e78346–e78346. 6 indexed citations

10.

Watanabe, Tsunamasa, et al.. (2013). Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0. Journal of Clinical Microbiology. 51(12). 4275–4276. 5 indexed citations

11.

Ikeda, Hitoshi, Ryosuke Tateishi, Kenichiro Enooku, et al.. (2011). Prediction of Hepatocellular Carcinoma Development by Plasma ADAMTS13 in Chronic Hepatitis B and C. Cancer Epidemiology Biomarkers & Prevention. 20(10). 2204–2211. 15 indexed citations

12.

Ikeda, Hitoshi, Ryunosuke Ohkawa, Naoko Watanabe, et al.. (2010). Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clinica Chimica Acta. 411(9-10). 765–770. 36 indexed citations

13.

Ikeda, Hitoshi, Naoko Watanabe, Isao Ishii, et al.. (2008). Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. Journal of Lipid Research. 50(3). 556–564. 106 indexed citations

14.

Tomiya, Tomoaki, Takako Nishikawa, Yukiko Inoue, et al.. (2007). Leucine stimulates HGF production by hepatic stellate cells through mTOR pathway. Biochemical and Biophysical Research Communications. 358(1). 176–180. 26 indexed citations

15.

Nishikawa, Takako, Tomoaki Tomiya, Natsuko Ohtomo, et al.. (2007). Stimulation by glutamine and proline of HGF production in hepatic stellate cells. Biochemical and Biophysical Research Communications. 363(4). 978–982. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact